As a catalyst for innovation, Riverside celebrates the many discoveries and continuing research of its colleges and universities. One of the most recent accomplishments that is likely to have a global impact came from chemists at UCR who developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.
On February 19, UCR Today reported that Michael Pirrung, a distinguished professor of chemistry at UC Riverside, announced the development of TIR-199 in a lecture he gave that same day at the 5th International Conference on Drug Discovery and Therapy, held in Dubai, UAE. The TIR-199 compound targets the “proteasome,” a cellular complex in kidney cancer cells, and operates like the garbage dump of a cell by breaking down proteins.
The TIR-199 research project at UC Riverside began about four years ago after a multidisciplinary, international team reported on a class of compounds that act on the proteasome. Encouraged by early results, Pirrung submitted TIR-199 samples to the National Cancer Institute at the National Institutes of Health, where the compound was subjected to a rigorous 60-cell screening used routinely to test compounds for their effectiveness in battling 60 kinds of cancer, including leukemia, lung, colon, brain, breast, ovarian prostate and renal cancers.
“We were very excited when the NCI informed us that TIR-199 has excellent potential to be moved to drug development because of its selective activity against renal cancer,” Pirrung said. “This is good news also because the NCI scientists told us there really are no good drugs out there to fight renal cancer.”
The UCR Office of Technology Commercialization has filed a patent application on TIR-199 and is currently seeking partners in industry interested in developing the compound commercially. Several biotechnology companies have already shown interest.
For more information on the TIR-199 compound and the research/commercialization project, read the full article as published by UCR Today.